Brokerages Set Biogen Inc. (NASDAQ:BIIB) PT at $227.07

Biogen Inc. (NASDAQ:BIIB) has been given an average rating of “Moderate Buy” by the thirty-three research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $227.7857.

BIIB has been the subject of several analyst reports. Wolfe Research upgraded Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a report on Thursday, August 13th. Evercore started coverage on Biogen in a research report on Friday, May 15th. They set an “outperform” rating for the company. Needham & Company LLC raised their price target on Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Truist Financial raised Biogen from a “hold” rating to a “buy” rating and boosted their price target for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. Finally, Rothschild & Co Redburn upped their price objective on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th.

Biogen Stock Performance

BIIB opened at $221.50 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The company has a market capitalization of $32.73 billion, a price-to-earnings ratio of 39.20, a P/E/G ratio of 6.89 and a beta of 0.17. Biogen has a 1 year low of $131.52 and a 1 year high of $222.85. The business’s 50-day moving average price is $207.37 and its two-hundred day moving average price is $195.52.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the prior year, the firm posted $5.47 EPS. The business’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts expect that Biogen will post 12.39 EPS for the current fiscal year.

Institutional Trading of Biogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its position in shares of Biogen by 21,439.6% in the 2nd quarter. California State Teachers Retirement System now owns 47,535,145 shares of the biotechnology company’s stock valued at $10,270,443,000 after acquiring an additional 47,314,458 shares during the period. BlackRock Inc. bought a new stake in shares of Biogen in the 2nd quarter valued at about $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen in the 2nd quarter valued at about $3,274,304,000. Norges Bank acquired a new stake in Biogen in the 4th quarter valued at about $464,408,000. Finally, Boston Partners acquired a new stake in Biogen in the 4th quarter valued at about $302,815,000. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.